Literature DB >> 19520710

Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro.

Petra A B Klemmt1, Fang Liu, Janet G Carver, Celine Jones, Dorothea Brosi, Jonathan Adamson, Helen J Mardon, Enda McVeigh.   

Abstract

BACKGROUND: Gonadotrophin releasing hormone (GnRH) analogues are widely used in IVF programmes as a method of suppressing the luteinizing hormone (LH) surge prior to ovarian stimulation, but their roles outside the pituitary remain relatively unknown. A 2002 Cochrane review (Al-Inany et al. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD001750) described lower pregnancy rates in women administered with GnRH antagonist, compared with those using an agonist, as part of an IVF programme, despite the fact that GnRH antagonist is a more effective repressor of LH. This study aimed to analyse the in-vitro effects of GnRH analogues on the decidualizing endometrium, blastocyst invasion and GnRH receptor expression in fertile women.
METHODS: We analysed the in-vitro decidualization capacity of endometrial stromal cells, derived from fertile women during the implantation window, in the presence of GnRH analogues. The influence of GnRH analogues on GnRH receptor expression and blastocyst invasion was assessed by in-vitro assays of biomedical marker secretion, immunoblots and blastocyst attachment to the stromal extracellular matrix.
RESULTS: We demonstrate that, at the concentrations and time periods used, GnRH analogues did not significantly influence the extent of decidualization of endometrial stromal cells. In addition, no adverse effect of GnRH analogues was seen on human blastocyst invasion.
CONCLUSIONS: We suggest that GnRH analogues affect neither the capacity of the endometrium to support invasion nor the invasive potential of the blastocyst in the early stages of implantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520710      PMCID: PMC2727401          DOI: 10.1093/humrep/dep181

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  21 in total

1.  The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.

Authors:  Katya Chobotova; Mary-Elizabeth Muchmore; Janet Carver; Hyung-J Yoo; Sanjiv Manek; William J Gullick; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 2.  The endometrium in stimulated cycles for IVF.

Authors:  Claire Bourgain; Paul Devroey
Journal:  Hum Reprod Update       Date:  2003 Nov-Dec       Impact factor: 15.610

3.  Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation.

Authors:  E M Casañ; F Raga; F Bonilla-Musoles; M L Polan
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 4.  Actions of gonadotrophins on the uterus.

Authors:  M Shemesh
Journal:  Reproduction       Date:  2001-06       Impact factor: 3.906

5.  Possible direct effect of gonadotropin releasing hormone on human endometrium and decidua.

Authors:  S Takeuchi; N Futamura; H Minoura; N Toyoda
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

6.  Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients.

Authors:  Young Sik Choi; Seung-Yup Ku; Byung-Chul Jee; Chang-Suk Suh; Young Min Choi; Jung Gu Kim; Shin Yong Moon; Seok Hyun Kim
Journal:  Hum Reprod       Date:  2006-04-06       Impact factor: 6.918

7.  Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual Stromal cells in vitro.

Authors:  Chun-Shan Chou; Chen-Jei Tai; Colin D MacCalman; Peter C K Leung
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

8.  An in-vitro model for stromal invasion during implantation of the human blastocyst.

Authors:  Janet Carver; Karen Martin; Isabella Spyropoulou; David Barlow; Ian Sargent; Helen Mardon
Journal:  Hum Reprod       Date:  2003-02       Impact factor: 6.918

9.  Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles.

Authors:  Kostantinos Zikopoulos; Efstratios M Kolibianakis; Michael Camus; Herman Tournaye; Etienne Van den Abbeel; Hubert Joris; André Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2004-02       Impact factor: 7.329

10.  Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis.

Authors:  Gabriela F Meresman; Mariela A Bilotas; Eduardo Lombardi; Marta Tesone; Carlos Sueldo; Rosa I Barañao
Journal:  Hum Reprod       Date:  2003-09       Impact factor: 6.918

View more
  5 in total

Review 1.  Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis.

Authors:  João Batista A Oliveira; Ricardo Baruffi; Cláudia G Petersen; Ana L Mauri; Mario Cavagna; José G Franco
Journal:  Reprod Biol Endocrinol       Date:  2010-09-08       Impact factor: 5.211

2.  Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study.

Authors:  Céline Pirard; Ernest Loumaye; Pascale Laurent; Christine Wyns
Journal:  Int J Endocrinol       Date:  2015-04-05       Impact factor: 3.257

3.  Conditional loss of ERK1 and ERK2 results in abnormal placentation and delayed parturition in the mouse.

Authors:  Jessica L Brown; Jennifer L Sones; Cynthia N Angulo; Keelin Abbott; Andrew D Miller; Ulrich Boehm; Mark S Roberson
Journal:  Sci Rep       Date:  2019-07-03       Impact factor: 4.379

4.  Prolonged GnRH suppression period in controlled ovarian hyperstimulation cycles: Impacts on IVF outcomes?

Authors:  Ozlem Gun Eryilmaz; Esma Sarikaya; Melike Doganay; Leyla Mollamahmutoglu; Nedim Cicek
Journal:  Iran J Reprod Med       Date:  2012-03

5.  The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS.

Authors:  Maryam Eftekhar; Sepideh Miraj; Zahrasadat Mortazavifar
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.